引用本文
  • 吴建国,罗蓓,朱忠政,等.顺铂腹腔化疗联合微波热疗治疗消化系统癌性腹水的临床疗效[J].同济大学学报(医学版),2020,41(5):650-653.    [点击复制]
  • WU Jian-guo,LUO Bei,ZHU Zhong-zheng,et al.Efficacy of cisplatin intraperitoneal chemotherapy combined with microwave hyperthermia in treatment of cancerous ascites[J].同济大学学报(医学版),2020,41(5):650-653.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 24次   下载 20 本文二维码信息
码上扫一扫!
顺铂腹腔化疗联合微波热疗治疗消化系统癌性腹水的临床疗效
吴建国,罗蓓,朱忠政,许青
0
(同济大学附属第十人民医院肿瘤科,上海200070)
摘要:
目的评估顺铂腹腔灌注化疗联合微波热疗治疗消化系统肿瘤癌性腹水的疗效及安全性。方法2018年10月1日—2019年9月30日收治的109例癌性腹水患者,随机分为处理组(n=58)和对照组(n=51),均腹腔置管放尽腹水。处理组于腹腔内灌注顺铂后进行微波热疗,对照组单纯腹腔内灌注顺铂,2周为1个疗程;4个疗程后评价两种方法对癌性腹水的有效性以及安全性。结果处理组腹水消退率(74.14%)、KPS评分稳定率(77.59%)均高于对照组(60.78%、62.75%,P<0.05)。处理组6、12、24个月生存率(87.93%、67.24%、25.86%)均高于同期对照组(80.39%、50.98%、15.52%)(均P<0.05)。处理组和对照组的恶心、呕吐、肝肾功能损害以及骨髓抑制等不良反应发生率均较低,差异无统计学意义(6.90% vs 7.84%,P>0.05)。结论顺铂腹腔灌注化疗联合微波热疗治疗癌性腹水疗效较好,能明显消除腹水,延长生存期,改善患者生活质量,安全性好,值得临床推广。
关键词:  微波热疗  腹腔化疗  癌性腹水
DOI:10.16118/j.1008-0392.2020.05.018
投稿时间:2019-12-11
基金项目:吴阶平医学基金会临床科研专项基金(320.6750.18523)
Efficacy of cisplatin intraperitoneal chemotherapy combined with microwave hyperthermia in treatment of cancerous ascites
WU Jian-guo,LUO Bei,ZHU Zhong-zheng,XU Qing
(Dept. of Oncology, Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200070, China)
Abstract:
ObjectiveTo evaluate the efficacy and safety of cisplatin intraperitoneal chemotherapy combined with microwave hyperthermia in the treatment of cancerous ascites. MethodsOne hundred and nine patients with cancerous ascites from October 2018 to September 2019 were randomly divided into two groups:58 patients in study group underwent microwave hyperthermia after intraperitoneal infusion of cisplatin; while 51 patients in control group received intraperitoneal cisplatin only. One treatment course lasted for 2 weeks, after 4 courses the efficacy and safety of the two methods were evaluated. ResultsThe regression rate(74.14% vs 60.78%, P<0.05), KPS score stability rate(77.59% vs 62.75%, P<0.05), 6-month survival rate(87.93% vs 80.39%, P<0.05), 12-month survival rate(67.24% vs 50.98%, P<0.05) and 24-month survival rate(25.86% vs 15.52%, P<0.05) in study group were all higher than those in control group. There were no significant differences in the incidence of adverse reactions such as vomiting, renal impairment, and bone marrow suppression between two groups(6.90% vs 7.84%, P>0.05). ConclusionCisplatin intraperitoneal chemotherapy combined with microwave hyperthermia is effective and safe in treating digestive cancerous ascites. This method can significantly eliminate ascites, extend survival, improve the quality of life of patients.
Key words:  microwave hyperthermia  intraperitoneal chemotherapy  cancerous ascites

您是第2295847位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计